Entering the Iraqi healthcare market is not only about product registration — it is about building reliable pharmaceutical distribution channels in Iraq that connect manufacturers with pharmacies, hospitals, clinics, and public-sector buyers. Iraq’s pharmaceutical market is worth more than USD 3 billion, and over 90 percent of medicines used in the country are imported, mainly from India, Jordan, Iran, and Turkey. For any international pharmaceutical, supplement, or medical device company, understanding how products move from the factory gate to the patient is the difference between a slow, uncertain launch and a structured, sustainable presence. This guide breaks down how pharmaceutical distribution channels in Iraq actually work, who the key players are, and how to choose the right partner.
What Is Pharmaceutical Distribution?
Pharmaceutical distribution is the structured process of moving medicines, supplements, medical devices, and OTC products from manufacturers to the end user, whether that is a pharmacy, a hospital, a clinic, or a government procurement body. It covers importation, customs clearance, warehousing under proper storage conditions, inventory management, order fulfilment, and last-mile delivery to thousands of points of sale across a country.
In a market like Iraq, pharmaceutical distribution marketing goes beyond logistics. It includes building relationships with wholesalers, training sales representatives, managing tender submissions, and ensuring that a registered product is not only available but actively promoted to physicians and pharmacists. Without this combined logistical and commercial layer, even a fully registered drug can struggle to reach shelves consistently, which is why distribution channels in the pharmaceutical industry are treated as a core part of any market-entry strategy.
Various Channels of Distribution in Pharmaceutical Marketing
There is no single answer to what are the channels of distribution in the pharmaceutical sector — most markets, including Iraq, run on a mix of models depending on the product category and target customer.
The most common channels of distribution in pharmaceutical marketing include:
- Manufacturer to national distributor to pharmacy — the standard route for prescription and OTC medicines sold through retail pharmacies.
- Manufacturer to hospital or clinic directly — used for specialty and hospital-only medicines, medical devices, and aesthetic products.
- Manufacturer to KIMADIA (public tenders) — the government route for medicines supplied to public hospitals and health facilities.
- Manufacturer to sub-distributor to regional wholesaler — used to reach less-centralized cities and provinces.
- E-commerce and pharmacy delivery platforms — a growing channel for OTC and wellness products.
Choosing between these routes depends on the product’s category, its shelf life, whether it requires cold-chain handling, and whether the brand is targeting the private sector, the public sector, or both. Companies planning how to enter the Iraqi pharmaceutical market usually need a distributor capable of operating across more than one of these channels at once.
List of the Different Members in Pharmaceutical Distribution Channels
To fully explain the channels of distribution, it helps to look at who actually sits inside them. In Iraq, the members of a typical pharmaceutical distribution channel include:
1. Manufacturers and international brand owners — the source of the product, responsible for quality, regulatory dossiers, and supply.
2. Licensed importers and local distributors — companies that hold the import license, manage customs clearance, and own the local warehousing and delivery network. Several private distributors operate nationwide in Iraq, alongside a growing number of regional players covering both the Kurdistan Region and central and southern Iraq.
3. Wholesalers and sub-distributors — intermediaries who buy in bulk from the main distributor and redistribute to smaller pharmacies in secondary cities and provinces.
4. Retail pharmacies and pharmacy chains — the final private-sector point of sale for most OTC and prescription products.
5. Hospitals, clinics, and medical centers — direct buyers for hospital-only medicines, medical devices, and aesthetic products.
6. KIMADIA — the Ministry of Health agency responsible for centralized public procurement of medicines for government hospitals.
7. Sales and medical representatives — the commercial layer that promotes products to physicians, pharmacists, and procurement committees.
Each member plays a distinct role, and a weak link anywhere in this chain — a distributor with poor geographic reach, or a wholesaler with no cold-chain capability — can directly limit how far a product actually travels.
Functions of Distribution Channels in the Iraqi Market
Beyond simply moving boxes, the functions of distribution channels in pharma cover several layers of value. A capable distributor in Iraq typically manages:
- Import and regulatory coordination, working alongside the drug registration process in Iraq
- Warehousing and inventory control, including cold-chain storage for temperature-sensitive products
- Order processing and last-mile delivery to pharmacies, hospitals, and clinics nationwide
- Sales force deployment and pharmacy or clinic engagement
- Market feedback, demand forecasting, and sales reporting back to the manufacturer
- Risk absorption, including currency fluctuation and slow-paying accounts
These functions explain why drug distribution channels are treated as a long-term partnership rather than a one-time logistics contract — the distributor effectively becomes the manufacturer’s operational presence on the ground.
The Iraqi Pharmaceutical Market: Size and Structure
Understanding pharma distribution channels in Iraq requires some context on the market itself. Iraq’s pharmaceutical market is valued at more than USD 3 billion as of 2024, and distribution and retail activity is mostly run by the private sector, while public procurement is centralized through KIMADIA. Currency fluctuations and inflation directly affect medicine pricing and supply chain dynamics, and healthcare spending remains around 4 percent of GDP, lower than regional peers, which continues to create room for private-sector and foreign investment in both distribution and healthcare services.
For a deeper look at market fundamentals, see our breakdown of the Iraq pharmaceutical market size and the broader Iraq healthcare market overview, both of which shape how distribution networks are structured city by city.
Public vs Private Sector Distribution Channels
Iraq effectively runs two parallel pharmaceutical distribution channels. The public channel flows through KIMADIA, which purchases medicines through centralized tenders for government hospitals and primary healthcare centers — a route that favors manufacturers with strong pricing, registered dossiers, and tender experience.
The private channel is far more fragmented, made up of licensed importers, wholesalers, and thousands of independent pharmacies spread across Baghdad, Basra, Erbil, Sulaymaniyah, Mosul, and smaller provinces. Most international brands entering Iraq rely on this private channel first, since it offers faster market access than public tenders, before later expanding into institutional and government supply once local registration and references are established.
Choosing the Right Pharmaceutical Distribution Partner
Not every distributor that claims “nationwide coverage” actually delivers it. When evaluating pharmaceutical distribution channels in Iraq, manufacturers should look at:
- Geographic reach — does the distributor genuinely service secondary cities, or only Baghdad?
- Category expertise — hospital medicines, OTC, supplements, and medical aesthetics each need different sales approaches.
- Regulatory capability — familiarity with the drug registration process in Iraq, medical device registration, and supplement registration requirements.
- Cold-chain and storage infrastructure for sensitive products.
- Reporting transparency — can they provide real sales data, not just shipment confirmations?
A distributor with genuine access to pharmacies, clinics, and public-sector buyers is worth far more than one with a large but shallow network. This is where structured local partners add the most value, offering services that combine logistics with real commercial execution rather than pure warehousing.
How Lamassu Health Supports Distribution in Iraq
Lamassu Health works with international pharmaceutical, OTC, supplement, and medical aesthetics brands to build the exact kind of structured presence described above. Rather than treating distribution as a single transaction, Lamassu Health combines regulatory coordination, nationwide logistics, pharmacy and clinic engagement, and ongoing sales reporting into one integrated route to market.
This approach covers the full journey — from initial market assessment, through registration support, to physical distribution and brand activation across Iraq’s private and institutional channels. Brands looking to move beyond a single-city presence can explore the full range of services offered, including nationwide distribution, tender readiness, and commercial launch management, all designed around the realities of pharmaceutical distribution channels in Iraq rather than a generic playbook.
Conclusion
Pharmaceutical distribution channels in Iraq are shaped by a mix of private wholesalers, licensed importers, retail pharmacies, hospitals, and the public KIMADIA system — each requiring a different commercial approach. Manufacturers that treat distribution as an afterthought to registration typically struggle with inconsistent availability and weak market feedback. Those that plan for it from day one, choosing a partner with real geographic reach and category expertise, are far more likely to build a sustainable position. Whether the goal is private-sector pharmacy coverage or long-term public tender access, understanding these channels is the first real step toward a successful launch in Iraq.
Frequently Asked Questions
What are the 8 types of distribution channels?
Distribution channels are generally grouped into models such as direct sales, wholesalers, retailers, distributors, brokers and agents, dual distribution, franchising, and e-commerce or online channels. In pharma specifically, the most relevant of these are direct-to-hospital sales, distributor-to-pharmacy networks, wholesaler-led regional distribution, and public-tender procurement.
Who are the big 3 pharma distributors?
Globally, the three dominant pharmaceutical distributors are McKesson Corporation, Cencora (formerly AmerisourceBergen), and Cardinal Health, which together control well over 90 percent of the U.S. pharmaceutical distribution market by revenue. Iraq’s market works differently, with distribution led by local and regional private companies rather than global wholesalers, alongside public procurement through KIMADIA.
What are the four main channels of distribution?
The four main channels are typically defined as direct selling (no intermediaries), selling through intermediaries such as wholesalers and retailers, dual distribution (a mix of both), and reverse logistics for returns or recalls. Pharmaceutical companies in Iraq most commonly rely on the second model, using licensed distributors and wholesalers to reach pharmacies nationwide.
Who are the big 3 distributors?
In a general business context, this usually refers to the same three companies noted above — McKesson, Cencora, and Cardinal Health — since they rank among the largest distributors across the healthcare sector as a whole, not only within pharmaceuticals. At a country level like Iraq, market leadership is far more fragmented among local and regional distribution companies rather than a small handful of global players.